Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HDP 101

Next Previous
Drug Profile

HDP 101

Alternative Names: HDP-101; HDP101-ATAC

Latest Information Update: 20 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Heidelberg Pharma AG
  • Developer Heidelberg Pharma AG; Huadong Medicine
  • Class Amanitins; Antineoplastics; Cyclic peptides; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 20 Apr 2026 Discontinued - Preclinical for Multiple myeloma in Germany (SC) (Heidelberg Pharma pipeline, April 2026)
  • 17 Mar 2026 Phase-I clinical trials in Multiple myeloma (In infants, In neonates, In children, In adolescents, In adults, Second-line therapy or greater) in China (IV) (NCT07529782)
  • 12 Jun 2025 Updated adverse events and efficacy data from a phase-I/II trial in Multiple myeloma presented at the 30th Congress of the European Haematology Association (EHA-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top